Literature DB >> 21136900

The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy.

Kasper Rossing1, Harald Mischak, Peter Rossing, Joost P Schanstra, Alex Wiseman, David M Maahs.   

Abstract

Diabetes represents one of the main chronic diseases worldwide. Diabetes and its associated complications may be detectable even at early stages in the urinary proteome. In this article we review the current literature on urinary proteomics applied to the study of diabetes and diabetic complications. Further, we present recent data that strongly indicate urinary proteome analysis may be a valuable tool in detecting diabetes-associated pathophysiological changes at an early stage, and also may enable assessment of disease progression and efficacy of therapy. Current data indicate that collagen-derived peptides represent one of the main peptidic components in urine, which are consistently found at reduced levels in diabetes. It is tempting to speculate that this decrease in urinary collagen-derived peptides is related to an increase in extracellular matrix deposition which is a major complication in diabetes. Therefore, urinary proteome analysis might enable noninvasive assessment of this process at an early stage via determination of specific collagen fragments. This may open an avenue towards targeted therapeutic intervention.
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2008        PMID: 21136900     DOI: 10.1002/prca.200780166

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  24 in total

Review 1.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

2.  Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Marion Haubitz; David M Good; Alexander Woywodt; Hermann Haller; Harald Rupprecht; Dan Theodorescu; Mohammed Dakna; Joshua J Coon; Harald Mischak
Journal:  Mol Cell Proteomics       Date:  2009-06-28       Impact factor: 5.911

Review 3.  Proteomic urinary biomarker approach in renal disease: from discovery to implementation.

Authors:  Joost P Schanstra; Harald Mischak
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

4.  Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

Authors:  David M Good; Petra Zürbig; Angel Argilés; Hartwig W Bauer; Georg Behrens; Joshua J Coon; Mohammed Dakna; Stéphane Decramer; Christian Delles; Anna F Dominiczak; Jochen H H Ehrich; Frank Eitner; Danilo Fliser; Moritz Frommberger; Arnold Ganser; Mark A Girolami; Igor Golovko; Wilfried Gwinner; Marion Haubitz; Stefan Herget-Rosenthal; Joachim Jankowski; Holger Jahn; George Jerums; Bruce A Julian; Markus Kellmann; Volker Kliem; Walter Kolch; Andrzej S Krolewski; Mario Luppi; Ziad Massy; Michael Melter; Christian Neusüss; Jan Novak; Karlheinz Peter; Kasper Rossing; Harald Rupprecht; Joost P Schanstra; Eric Schiffer; Jens-Uwe Stolzenburg; Lise Tarnow; Dan Theodorescu; Visith Thongboonkerd; Raymond Vanholder; Eva M Weissinger; Harald Mischak; Philippe Schmitt-Kopplin
Journal:  Mol Cell Proteomics       Date:  2010-07-08       Impact factor: 5.911

5.  Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Authors:  Justyna Siwy; Joost P Schanstra; Angel Argiles; Stephan J L Bakker; Joachim Beige; Petr Boucek; Korbinian Brand; Christian Delles; Flore Duranton; Beatriz Fernandez-Fernandez; Marie-Luise Jankowski; Mohammad Al Khatib; Thomas Kunt; Maria Lajer; Ralf Lichtinghagen; Morten Lindhardt; David M Maahs; Harald Mischak; William Mullen; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Frederik Persson; John R Petrie; Johannes M Roob; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Janet Snell-Bergeon; Goce Spasovski; Olivera Stojceva-Taneva; Matias Trillini; Heiko von der Leyen; Brigitte M Winklhofer-Roob; Petra Zürbig; Joachim Jankowski
Journal:  Nephrol Dial Transplant       Date:  2014-03-02       Impact factor: 5.992

6.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Authors:  Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Journal:  BMC Nephrol       Date:  2010-11-01       Impact factor: 2.388

7.  Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.

Authors:  David M Maahs; Justyna Siwy; Angel Argilés; Marie Cerna; Christian Delles; Anna F Dominiczak; Nathalie Gayrard; Alexander Iphöfer; Lothar Jänsch; George Jerums; Karel Medek; Harald Mischak; Gerjan J Navis; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Eric Schiffer; Roland E Schmieder; Thomas C Wascher; Brigitte M Winklhofer-Roob; Lukas U Zimmerli; Petra Zürbig; Janet K Snell-Bergeon
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

Review 8.  Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Authors:  Jochen Metzger; Peter B Luppa; David M Good; Harald Mischak
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

9.  Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

Authors:  Janet K Snell-Bergeon; David M Maahs; Lorraine G Ogden; Gregory L Kinney; John E Hokanson; Eric Schiffer; Marian Rewers; Harald Mischak
Journal:  Diabetes Technol Ther       Date:  2009-01       Impact factor: 6.118

Review 10.  Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments.

Authors:  Harald Mischak; Joshua J Coon; Jan Novak; Eva M Weissinger; Joost P Schanstra; Anna F Dominiczak
Journal:  Mass Spectrom Rev       Date:  2009 Sep-Oct       Impact factor: 10.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.